Interestingly, in this study, we provide additional proof of the proinflammatory response’s effects in preclinical models with pathological conditions linked to AD and PD, as well as the ability of LRRK2 kinase inhibition to attenuate them. Here, LRRK2 is linked to Parkinson disease.